Pharmaceuticals

TMSP

TMSP released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 44.39 M, actual EPS CNY 0.0313

TMSP to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

TMSP released FY2025 Q4 earnings on April 17 After-Market (BJT), actual revenue CNY 52.81 M, actual EPS CNY 0.028

TMSP released FY2025 Annual Earnings on April 17 After-Market (BJT), Actual Revenue: CNY 211.75 M, Actual EPS: CNY 0.1447

TMSP to Release FY2025 Earnings Report on April 18 After-Market (BJT)

TMSP released FY2025 Q3 earnings on October 28 Pre-Market (BJT), actual revenue CNY 55.34 M, actual EPS CNY 0.0325

TMSP released FY2025 9 Months Earnings on October 28 Pre-Market BJT, actual revenue CNY 158.94 M, actual EPS CNY 0.1167

TMSP FY2025 Q3 Earnings Release on October 29 Pre-Market BJT

TMSP released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue CNY 51.3 M, actual EPS CNY 0.0424

TMSP released FY2025 Semi-Annual Earnings on August 27 Pre-Market (BJT), actual revenue CNY 103.6 M, actual EPS CNY 0.0842

TMSP FY2025 Semi-Annual Earnings Release on August 28, 2025 (BJT)

Tianmu Pharmaceutical Announces 2025H1 Earnings Forecast

Tianmu Pharmaceutical Discusses Product Strategies and Innovative Drug Layout with Investors

Huangshan Tianmu Pharmaceutical Obtained Drug Re-registration Approval Notice

ST Muyao Reports Profitable First Quarter

TMSP released FY2025 Q1 earnings on April 27 After-Market BJT, actual revenue CNY 52.29 M, actual EPS CNY 0.0418

TMSP to Release FY2025 Q1 Earnings Report on April 28 After-Market BJT

TMSP released FY2024 Q4 earnings on March 31 After-Market (BJT), actual revenue CNY 92.62 M, actual EPS CNY 0.1562

TMSP released FY2024 Annual Earnings on March 31 After-Market (BJT), actual revenue CNY 217.3 M, actual EPS CNY 0.1252

TMSP to Release FY2024 Annual Earnings on April 1, 2025, After-Market BJT

002082

300086

600671

000623

The traditional Chinese medicine concept continues to rise, WBDE hits the limit up, Honz, TMSP, Zhenbao Island, JI LIN AO DONG and others follow suit

Zhitong

WBDE

Honz

JI LIN AO DONG

According to the Zhitong Finance APP, TMSP announced that its wholly-owned subsidiary Huangshan TMSP Co., Ltd. (referred to as "Huangshan TMSP") recently received the approval notice for re-registration of several drugs, including Liuwei Dihuang Wan, issued by the Anhui Provincial Drug Administration. The acquisition of the above-mentioned drug re-registration approval notice ensures the stability and continuity of the company's drug production and sales qualifications, which has positive significance for the company's subsequent production, sales, and promotion

TMSP's subsidiary received the drug re-registration approval notice

TMSP announced that in the first half of 2025, operating revenue reached 104 million yuan, a year-on-year increase of 73.97%. Net profit was 10.2478 million yuan, compared to a loss of 18.5007 million yuan in the same period last year

TMSP: Net profit of 10.2478 million yuan in the first half of 2025, turning from loss to profit

600329

603858

As of now, 19 listed companies have released their semi-annual reports for 2025, among which companies like DRTG, JI LIN AO DONG, and BUCHANG PHARMA have seen their net profits double year-on-year. DRTG expects its net profit for the first half of the year to reach between 1.84 billion and 2 billion yuan, a year-on-year increase of 180% to 204%, mainly due to profits from equity sales. TMSP has turned losses into profits, with an overall improvement in profitability. The stock hit the daily limit today, with well-known speculative funds net buying 9.5309 million yuan

DRTG

BUCHANG PHARMA

Some traditional Chinese medicine stocks saw their net profits double year-on-year in the first half of the year

300573

The ophthalmology concept experienced a volatile rebound, with TMSP hitting the limit up, followed by gains in Xingqi Pharmaceutical, Laimei Pharmaceutical, Nosseland, Daheng Technology, Guanhao Biological, and Doctor Glasses

Xingqi Pharmaceutical

Ophthalmology concept experiences a volatile rebound, TMSP hits the limit up

TMSP announced that its subsidiary has received the drug re-registration approval notice issued by the Anhui Provincial Drug Administration, covering various drugs, including kidney-tonifying tablets and cold relief tablets. The approval is valid until 2030 and is applicable to multiple symptoms. This move will positively impact the company's production, sales, and promotion

TMSP: Notification of Drug Re-registration Approval from Subsidiary

002951

300368

002259

300163

The early trading session saw active performance in the concept of "removing the cap," with APLUS hitting the 20% limit up. Previously, JiuZhiTang, Jinshi Technology, Zhongjia Bochuang, and Yongyue Technology also reached the limit up, while Huijin, Weidi, SHENGDAFORESTRY, and TMSP had notable gains

Jinshi Technology

Huijin

SHENGDAFORESTRY

APLUS

YONGYUE

VITI

ZJBC

The concept of "removing the cap" was active in the morning session, with multiple stocks including APLUS hitting the daily limit

TMSP announced that its wholly-owned subsidiary, Huangshan TMSP Co., Ltd., recently received the "Drug Re-registration Approval Notice" issued by the Anhui Provincial Drug Administration. The notice involves drugs such as Shenmai Drink, Shedan Chuanbei Liquid, Qiju Dihuang Oral Liquid, Nao Xin Shu Oral Liquid, and Xiaoshuan Oral Liquid. The acquisition of the above-mentioned drug re-registration approval notice ensures the stability and continuity of the company's drug production and sales qualifications, which has positive significance for the company's subsequent production, sales, promotion, and other activities

TMSP: Wholly-owned subsidiary receives drug re-registration approval notice

According to the Zhitong Finance APP, ST TMSP announced that the company's stock will be suspended for one day on May 19, 2025, and will resume trading on May 20, 2025, with other risk warnings lifted. After the removal of the risk warning, the stock abbreviation will change from "ST TMSP" to "Tianmu Pharmaceutical," and the stock will be traded outside the risk warning board. The daily price fluctuation limit for the company's stock will change from 5% to 10%

ST TMSP stock cancels other risk warnings and will be suspended for 1 day on May 19

According to the Zhitong Finance APP, ST TMSP released its first-quarter report for 2025. The company's first-quarter operating revenue was 52.2935 million yuan, a year-on-year increase of 88.55%; the net profit attributable to shareholders of the listed company was 5.0943 million yuan, turning a profit; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 3.6575 million yuan, turning a profit; basic earnings per share were 0.0418 yuan/share

ST TMSP released its first-quarter performance, with a net profit attributable to shareholders of RMB 5.0943 million, turning a profit from a loss

TMSP(600671.SH)